Zacks Investment Research
29 Oct 2026, 14:55 UTC · 1h ago
Impact · against what's priced in
The article suggests significant upside for Cullinan Therapeutics based on analyst price targets and earnings revisions, but since this data is based on public consensus, it lacks a catalyst for immediate price movement.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
Wall Street analysts have a mean price target of $35.73 for Cullinan Therapeutics (CGEM), representing a 129.6% upside from the current price of $15.56.
Priced inanalysis of existing analyst targets
So whatThe distance between the current price and the lowest target of $27.00 suggests a minimum projected gain of 73.5%.
More positive than 92% of claims this week
Continue reading
5 related stories
While the mean price target of $35.73 and positive earnings revisions suggest upside, these are lagging indicators based on analyst consensus rather than new operational developments.
Read from the article alone
Scored by the NIS engine · methodology.
There is a strong agreement among analysts regarding positive revisions to CGEM's earnings estimates.
Priced indiscussion of earnings estimate trends
So whatUpward revisions typically lead to higher EPS estimates in the next quarterly print, supporting a higher valuation multiple.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company has a significant average analyst price target upside of 129.6% and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
+2.1%
Price agrees with the score
$15.89 vs $15.56 close before publication (Oct 28) · not market-adjusted
CGEM chart →
